Related Experiment Video

Updated: Aug 14, 2026

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer

Walter H Gotlieb1, Ilan Bruchim, Jing Gu

  • 1Division of Gynecologic Oncology, McGill University, Montreal, Quebec, Canada. walter.gotlieb@mcgill.ca

Gynecologic Oncology
|November 23, 2005
PubMed
Abstract

Insights

This study investigated the anti-cancer effects of an insulin-like growth factor I receptor (IGF-IR) inhibitor in ovarian cancer cells. The inhibitor showed promising anti-neoplastic activity and sensitized cells to cisplatin, highlighting IGF-IR as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ovarian cancer cells (OVCAR-3, OVCAR-4) exhibit an autocrine loop involving insulin-like growth factor I (IGF-I) and IGF-II production, alongside IGF receptor (IGF-IR) expression.
  • This autocrine signaling pathway suggests IGF-IR as a potential therapeutic target in ovarian cancer.

Purpose of the Study:

  • To evaluate the preclinical anti-neoplastic activity of NVP-AEW541, a novel IGF-IR kinase inhibitor, in ovarian cancer.
  • To assess the compound's effect on ovarian cancer cell growth, apoptosis, and sensitivity to cisplatin.

Main Methods:

  • Ovarian cancer cell lines (OVCAR-3, OVCAR-4) were cultured and analyzed for IGF-I, IGF-II, and IGF-IR expression using ELISA, immunohistochemistry, and Western blotting.
  • Cytotoxicity was determined via Alamar assay, and apoptosis was assessed by flow cytometry and Western blotting for PARP.
  • The impact of NVP-AEW541 on downstream signaling pathways, specifically phosphorylated AKT, was also evaluated.

Main Results:

  • OVCAR-3 and OVCAR-4 cells demonstrated an autocrine IGF loop, confirming IGF-IR as a relevant target.
  • NVP-AEW541 exhibited significant growth inhibition in ovarian cancer cell lines, with IC50 values ranging from 5 to 15 microM.
  • The inhibitor induced apoptosis and sensitized cells to cisplatin in vitro, while also reducing phosphorylated AKT levels.

Conclusions:

  • Insulin-like growth factor I receptor (IGF-IR) represents a promising molecular target for ovarian cancer therapy.
  • NVP-AEW541 demonstrated anti-neoplastic effects in ovarian cancer models, although at higher concentrations than reported for multiple myeloma.
  • Further in vivo studies are warranted to investigate the clinical relevance and precise mechanisms of NVP-AEW541 in ovarian cancer treatment.

More Related Videos

Transplantation Into the Mouse Ovarian Fat Pad09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...